
Tepmetko ushers in a new era for MET-mutated lung cancer treatment
The treatment of MET-mutated non-small cell lung cancer (NSCLC) is entering a new era, driven by the approval and reimbursement of Tepmetko (ingredient: tepotinib), a targeted therapy that has redefined clinical expectations for a patient population …